ANTX – an2 therapeutics, inc. (US:NYSE)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

ANTX

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

7/7

06:00 pm

antx

Anthem (ANTX) had its "sell (d-)" rating reaffirmed by Weiss Ratings.

Low Report

Anthem (ANTX) had its "sell (d-)" rating reaffirmed by Weiss Ratings.

Report

6/14

01:00 am

antx

Anthem (ANTX) was upgraded by Wall Street Zen from "sell" to "hold".

Low Report

Anthem (ANTX) was upgraded by Wall Street Zen from "sell" to "hold".

Report

6/6

01:00 am

antx

Anthem (ANTX) was downgraded by Wall Street Zen from "hold" to "sell"

Low Report

Anthem (ANTX) was downgraded by Wall Street Zen from "hold" to "sell"

Report

6/4

07:46 am

antx

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease [Yahoo! Finance]

Medium Report

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease [Yahoo! Finance]

Report

6/4

07:00 am

antx

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

Medium Report

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

Report

5/21

07:00 am

antx

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

High Report

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

Report

5/14

09:00 am

antx

Anthem (ANTX) was upgraded by Leerink Partners from "market perform" to "outperform". They now have a $9.00 price target on the stock.

Low Report

Anthem (ANTX) was upgraded by Leerink Partners from "market perform" to "outperform". They now have a $9.00 price target on the stock.

Report

5/11

04:01 pm

antx

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Medium Report

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Report

5/7

04:01 pm

antx

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Medium Report

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Report

4/25

01:00 am

antx

Anthem (ANTX) was downgraded by Wall Street Zen from "hold" to "sell"

High Report

Anthem (ANTX) was downgraded by Wall Street Zen from "hold" to "sell"

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.